<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03730337</url>
  </required_header>
  <id_info>
    <org_study_id>ONO-7475-02 / ONO-4538-74</org_study_id>
    <nct_id>NCT03730337</nct_id>
  </id_info>
  <brief_title>Phase 1 Study of ONO-7475 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors</brief_title>
  <official_title>Open-label, Uncontrolled, Dose-escalation Study of ONO-7475 Given as Monotherapy and Combinations With ONO-4538 in Patients With Advanced or Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ono Pharmaceutical Co. Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ono Pharmaceutical Co. Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the tolerability and safety of ONO-7475 monotherapy and combinations with
      ONO-4538 in patients with advanced or metastatic solid tumors
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 17, 2018</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of paticipants with dose-limiting toxicities during the DLT evaluation period</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and severity of adverse events as assessed by CTCAE v4.0 to determine the tolerability and safety</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Cmax)</measure>
    <time_frame>Through study completion</time_frame>
    <description>Assessment of the maximum plasma concentration of ONO-7475 both alone and in combination with ONO-4538</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Tmax)</measure>
    <time_frame>Through study completion</time_frame>
    <description>Assessment of the time to reach maximum observed plasma concentration of ONO-7475 both alone and in combination with ONO-4538</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (AUC)</measure>
    <time_frame>Through study completion</time_frame>
    <description>Assessment of the plasma area under the curve of ONO-7475 both alone and in combination with ONO-4538</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Advanced or Metastatic Solid Tumors</condition>
  <arm_group>
    <arm_group_label>ONO-7475 monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ONO-7475 in combination with ONO-4538</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ONO-7475</intervention_name>
    <description>ONO-7475 specified dose on specified days</description>
    <arm_group_label>ONO-7475 monotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ONO-7475 + ONO-4538</intervention_name>
    <description>ONO-7475+ONO-4538 specified dose on specified days</description>
    <arm_group_label>ONO-7475 in combination with ONO-4538</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with histologically or cytologically confirmed advanced or metastatic solid
             tumors

          -  ECOG Performance Status 0ï½ž1

          -  Patients with life expectancy of at least 3 months

        Exclusion Criteria:

          -  Patients with history of severe allergy

          -  Patients with multiple cancers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hiroaki Hozumi</last_name>
    <role>Study Director</role>
    <affiliation>Ono Pharmaceutical Co. Ltd</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ono Pharmaceutical Co. Ltd Corporate communications</last_name>
    <email>y.tani@ono.co.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tokyo Clinical Site</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>October 30, 2018</study_first_submitted>
  <study_first_submitted_qc>November 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2018</study_first_posted>
  <last_update_submitted>November 2, 2018</last_update_submitted>
  <last_update_submitted_qc>November 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

